Acrivon Therapeutics (ACRV) News Today $4.92 -0.06 (-1.20%) (As of 12/29/2023 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTravere Therapeutics, Replimune among healthcare moversmsn.com - December 5 at 2:12 PMmarketbeat.com - December 4 at 4:03 PMAcrivon Therapeutics files for $300M mixed shelfmsn.com - December 1 at 7:08 PMAcrivon Announces Breakthrough Device Designation For ACR-368 OncoSignature Assaymarkets.businessinsider.com - November 28 at 10:10 AMAcrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer Assaymarketwatch.com - November 28 at 10:10 AMAcrivon Gets FDA's Breakthrough Device Designation For ACR-368 OncoSignature Assaymarkets.businessinsider.com - November 28 at 10:10 AMmarketbeat.com - November 13 at 9:53 AMAcrivon Therapeutics Stock (NASDAQ:ACRV), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 11 at 7:50 AMAnalyst Ratings for Acrivon Therapeuticsmarkets.businessinsider.com - November 10 at 9:00 PMPromising Future for Acrivon Therapeutics: Buy Rating Justified by Clinical Success and Expanding Market Opportunitiesmarkets.businessinsider.com - November 10 at 10:47 AMAnalysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Acrivon Therapeutics, Inc. (ACRV)markets.businessinsider.com - November 10 at 5:46 AMAcrivon Therapeutics GAAP EPS of -$0.66 beats by $0.04msn.com - November 9 at 5:35 PMRecap: Acrivon Therapeutics Q3 Earningsbenzinga.com - November 9 at 12:35 PMAcrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuticsfinance.yahoo.com - October 16 at 12:48 PMAcrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - October 14 at 1:02 PMAnalyst Expectations for Acrivon Therapeutics's Futuremarkets.businessinsider.com - October 5 at 7:05 PMMaxim Group Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy Recommendationmsn.com - October 5 at 7:05 PMmarketbeat.com - October 5 at 9:33 AMmarketbeat.com - October 4 at 9:33 AMAcrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - September 29 at 11:06 PMAcrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuticsfinance.yahoo.com - September 19 at 9:06 PMAcrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studiesfinance.yahoo.com - September 5 at 4:58 PMAcrivon Therapeutics to Participate in Two Investor Conferences in Septemberfinance.yahoo.com - August 30 at 10:50 AMJonesTrading Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy Recommendationmsn.com - August 18 at 6:39 PMAcrivon Therapeutics (NASDAQ:ACRV) Earns Buy Rating from Analysts at Jonestradingmarketbeat.com - August 18 at 8:17 AMAcrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - August 17 at 4:40 PMFederated Hermes Inc. Sells 209,675 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV)marketbeat.com - August 14 at 5:37 AMAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlightsfinanznachrichten.de - August 11 at 6:46 PMAcrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - August 11 at 6:46 PMAcrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairsfinance.yahoo.com - July 20 at 8:09 AMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Rating of "Buy" by Analystsmarketbeat.com - July 11 at 2:23 AMAcrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directorsfinance.yahoo.com - June 22 at 8:35 PMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 6.3% in Maymarketbeat.com - June 19 at 1:18 AMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Buy" by Brokeragesmarketbeat.com - June 16 at 4:22 AMAcrivon Therapeutics 10% Owner Trades Company's Stockbenzinga.com - June 15 at 3:59 PM284,201 Shares in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Purchased by HealthCor Management L.P.marketbeat.com - June 15 at 6:11 AMAcrivon Therapeutics to Present at the Jefferies Healthcare Conferencefinance.yahoo.com - June 2 at 10:15 AMAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Forecasted to Earn Q2 2023 Earnings of ($0.56) Per Sharemarketbeat.com - May 12 at 8:52 AMH.C. Wainwright Sticks to Their Buy Rating for Acrivon Therapeutics, Inc. (ACRV)markets.businessinsider.com - May 10 at 9:10 AMQ1 2023 Akoya Biosciences Inc Earnings Callfinance.yahoo.com - May 9 at 2:32 PMAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlightsfinanznachrichten.de - May 9 at 9:31 AMAcrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancerfinance.yahoo.com - May 9 at 9:31 AMAcrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - May 9 at 9:31 AMAcrivon Therapeutics, Inc. (ACRV) Receives a Buy from BMO Capitalmarkets.businessinsider.com - May 9 at 4:30 AMAcrivon Therapeutics, Inc.'s Lock-Up Period To Expire on May 15th (NASDAQ:ACRV)marketbeat.com - May 8 at 1:33 AMWe Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growthfinance.yahoo.com - May 7 at 10:45 AMHC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendationmsn.com - May 3 at 1:18 AMBank of Montreal Can Makes New Investment in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)marketbeat.com - May 2 at 4:48 AMAcrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conferencefinance.yahoo.com - April 25 at 10:46 AMAcrivon Therapeutics to Host Virtual Investor Event on May 1, 2023finance.yahoo.com - April 24 at 8:34 AM Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Media Mentions By Week ACRV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼1.890.84▲Average Medical News Sentiment ACRV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼11▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Organigram News Today Assertio News Today DiaMedica Therapeutics News Today IO Biotech News Today Kinnate Biopharma News Today Reviva Pharmaceuticals News Today BioLineRx News Today Atossa Therapeutics News Today Eton Pharmaceuticals News Today XBiotech News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:ACRV) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.